(Q51346211)

4 April 2018

title

Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. (English)

1 reference

4 April 2018

author

Jens Juul Holst

4

1 reference

4 April 2018

Mads Hornum

5

1 reference

4 April 2018

Bo Feldt-Rasmussen

6

1 reference

4 April 2018

Morten Jørgensen

object named as

Morten Jørgensen

3

0 references

author name string

Thomas Idorn

1

1 reference

4 April 2018

Filip K Knop

2

1 reference

4 April 2018

language of work or name

English

0 references

publication date

16 January 2013

1 reference

4 April 2018

published in

Kidney International

1 reference

4 April 2018

volume

83

1 reference

4 April 2018

issue

5

1 reference

4 April 2018

page(s)

915-923

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.1038/ki.2012.460

exact match

0 references

cites work

Hyperglucagonemia of renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Pathogenesis of glucose intolerance in uremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Pre-diabetes and arterial stiffness in uraemic patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Evidence for increased risk of prediabetes in the uremic patient

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

The incretin concept today

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

New developments in the incretin concept

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Impaired regulation of the incretin effect in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Reduced Incretin Effect in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Glucagon physiology and pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Glucagon physiology and pathophysiology in the light of new advances

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Use and abuse of HOMA modeling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Measurement of insulin resistance in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Gastric inhibitory polypeptide (GIP) and insulin release in response to oral and intravenous glucose in uremic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Renal effects on serum gastric inhibitory polypeptide (GIP).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Renal catabolism of truncated glucagon-like peptide 1

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.460

7 January 2021

Identifiers

DOI

10.1038/KI.2012.460

1 reference

4 April 2018

Dimensions Publication ID

0 references

1 reference

4 April 2018